These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 15958518

  • 41. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
    Won SH, Lee HJ, Jeong SJ, Lü J, Kim SH.
    Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
    [Abstract] [Full Text] [Related]

  • 42. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells.
    Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K.
    Int J Cancer; 2007 Apr 01; 120(7):1410-7. PubMed ID: 17205524
    [Abstract] [Full Text] [Related]

  • 43. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression.
    Lin DL, Whitney MC, Yao Z, Keller ET.
    Clin Cancer Res; 2001 Jun 01; 7(6):1773-81. PubMed ID: 11410519
    [Abstract] [Full Text] [Related]

  • 44. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.
    Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616
    [Abstract] [Full Text] [Related]

  • 45. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR, Mishra SK, Karnes RJ, Saleem M.
    Clin Cancer Res; 2011 Aug 15; 17(16):5379-91. PubMed ID: 21712449
    [Abstract] [Full Text] [Related]

  • 46. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T.
    J Urol; 2000 Sep 15; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [Abstract] [Full Text] [Related]

  • 47. Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line.
    Yin H, Radomska HS, Tenen DG, Glass J.
    BMC Cancer; 2006 Jun 14; 6():158. PubMed ID: 16774685
    [Abstract] [Full Text] [Related]

  • 48. D,L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells.
    Kim SH, Singh SV.
    Mol Cancer Ther; 2009 Jul 14; 8(7):1946-54. PubMed ID: 19584240
    [Abstract] [Full Text] [Related]

  • 49. Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells.
    Sundar SN, Kerekatte V, Equinozio CN, Doan VB, Bjeldanes LF, Firestone GL.
    Mol Endocrinol; 2006 Dec 14; 20(12):3070-82. PubMed ID: 16901971
    [Abstract] [Full Text] [Related]

  • 50. Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells.
    Chatterji U, Riby JE, Taniguchi T, Bjeldanes EL, Bjeldanes LF, Firestone GL.
    Carcinogenesis; 2004 Jul 14; 25(7):1119-28. PubMed ID: 14988219
    [Abstract] [Full Text] [Related]

  • 51. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.
    Cancer Gene Ther; 2000 Jul 14; 7(7):997-1007. PubMed ID: 10917202
    [Abstract] [Full Text] [Related]

  • 52. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
    Kim HJ, Park YI, Dong MS.
    Toxicol In Vitro; 2006 Oct 14; 20(7):1159-67. PubMed ID: 16621434
    [Abstract] [Full Text] [Related]

  • 53. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1999 Mar 14; 140(3):1205-12. PubMed ID: 10067845
    [Abstract] [Full Text] [Related]

  • 54. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 55. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L, Levenson AS.
    Anticancer Res; 2011 Oct 01; 31(10):3323-30. PubMed ID: 21965742
    [Abstract] [Full Text] [Related]

  • 56. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
    Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL.
    Endocr Relat Cancer; 2009 Dec 01; 16(4):1157-69. PubMed ID: 19635783
    [Abstract] [Full Text] [Related]

  • 57. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, Zhang D, Jiang J.
    Prostate; 2015 Aug 01; 75(11):1187-96. PubMed ID: 25894097
    [Abstract] [Full Text] [Related]

  • 58. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
    Koochekpour S, Lee TJ, Wang R, Sun Y, Delorme N, Hiraiwa M, Grabowski GA, Culig Z, Minokadeh A.
    J Cell Biochem; 2007 Jun 01; 101(3):631-41. PubMed ID: 17171640
    [Abstract] [Full Text] [Related]

  • 59. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
    Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM.
    Mol Cancer Ther; 2007 Jan 01; 6(1):51-60. PubMed ID: 17218635
    [Abstract] [Full Text] [Related]

  • 60. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
    Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, Kholkute SD, Sachdeva G.
    Endocr Relat Cancer; 2014 Jun 01; 21(3):473-86. PubMed ID: 24812058
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.